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Biliary atresia (BA) is an infantile inflammatory cholangiopathy of unknown etiology although epidemiologic studies and animal
models utilizing rotavirus (RV) have suggested a role for viral infection. Proinflammatory and profibrotic cytokines have been
detected in infants with BA. The purpose of our study was to investigate the susceptibility of human cholangiocytes (H69 cells) to
infection with RRV and to determine if this infection resulted in cytokine secretion. Infection of H69 cells by RRVwas noncytolytic
and resulted in a time-dependent increase in the release of both infectious virions and cytokines IL-6 and IL-8 into the supernate.
The greatest difference in cytokine supernatant levels between infected andmock-infected cells was noted at 24 hours postinfection
(h p.i.) for IL-8, 556 ± 111 versus 77 ± 68 pg/mL (𝑝 < 0.0001), and at 48 h p.i. for IL-6, 459 ± 64 versus 67 ± 2 pg/mL (𝑝 < 0.0001).
Production of both cytokines following RRV infection was significantly reduced by pretreating the H69 cells with inhibitors
of mitogen-activated protein kinase (MAPK). Conclusion. RRV can infect human cholangiocytes resulting in the production of
proinflammatory and profibrotic cytokines via the MAPK pathway. RRV-infected H69 cells could be a useful model system for
investigating the viral hypothesis of BA.
1. Introduction
Biliary atresia (BA) is a serious infantile liver disease of
unknown cause, occurring in ∼1 : 5,000–1 : 20,000 live births
[1]. We recently studied a group of 289 BA infants enrolled
in the Childhood Research and Education Network; 10%
had multiple congenital anomalies consistent with laterality
defects and 6% had multiple congenital anomalies not of
the laterality type [1]. It is assumed that these two forms
of BA begin prenatally and are probably genetic in origin
[2]. Approximately 65–90% of BA cases are of the perinatal
“acquired” type, the so-called “isolated” BA, not associated
with major congenital anomalies [1, 3]. Almost certainly the
three forms of BA have different etiologies [1]. Given the
characteristic time-space clustering and the expression of
proinflammatory and profibrotic cytokines both in the liver
and in the circulation, including interleukin-6 (IL-6) and
interleukin-8 (IL-8), isolated BA is believed by some to be
secondary to hepatobiliary viral infection [3, 4]. IL-6 and IL-
8 are of particular interest since IL-6 activates macrophages
[5] and IL-8 attracts neutrophils [6] and both cell types are
present abundantly around the cholangiocytes in the livers of
isolated human BA [7, 8]. Huang et al. [9] showed that IL-
8 mRNA was increased in livers of BA patients compared to
patients with choledochal cyst, both at the time of Kasai hep-
atic portoenterostomy and later, at the time of liver transplan-
tation. Hepatic IL-6 mRNA was also increased in children in
the late stage of BA [9].
Several viruses, including rotavirus (RV), have been
implicated as causative agents of BA, but reports have been
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inconclusive [10]. Extensive investigations by several groups
using RRV to induce BA in youngmice have focused renewed
attention on RV as an etiologic agent of BA [11]. Riepenhoff-
Talty et al. [12] first reported RV in hepatobiliary remnants of
infants with BA, where they found that 50% of their cohort
showed evidence of Group C RV infection [12].These studies
led to experiments which demonstrated that multiple animal
RVs could infect Hep G2 liver carcinoma cells [13].
RV is the most common cause of infantile gastroenteritis
worldwide, infecting virtually all children by 5 years of
age [14]. Although the infection was initially thought to be
restricted to the gastrointestinal tract, as RV requires trypsin-
like proteases for activation, a number of authors have
reported extraintestinal localization of RV in animal models,
including RV antigenemia and recovery in multiple organs
[15–17]. Furthermore Gilger et al. [18] reported that RV
infection of the liver of newborn human infants with immun-
odeficiency is plausible, perhaps via dendritic cell infection as
what has been shown in animal experiments [16]. BA is a rare
disease and infants usually present with cholestasis, not with
gastroenteritis. RV infection of newborns also is rare, ranging
from 5 to 15%, and it is asymptomatic in more than 90% of
cases [19].Thus the rarity of asymptomatic RV infection of the
neonate combined with the fact that RVmight infect the liver
at least provides a logical basis for implicating RV in some
cases of human BA.
Therefore, subsequent efforts were made to investigate
snap frozen hepatobiliary remnants from children with BA
for the presence of Groups A, B, and C RVs [20]. Failure to
identify RV in any of these samples led to the conclusion that
RV was not commonly involved in the etiology of acquired
BA. However, it was later observed that, in mice infected with
RRV on the first day of life, the virus cannot be detected in
their liver at 2 weeks of age, when the hepatobiliary disease is
evident [11], leading us to a reassessment of previous conclu-
sions.
We recently studied the seroprevalence of Group A and
Group C RV in infants with BA and cholestatic controls stud-
ied during the RV season in the United States (December–
May) in the pre-RV vaccine era. The overall prevalence of
asymptomatic Group A RV infection found in our study was
higher than the 5% previously published rates in this age
group. It is of interest that, depending on the sensitivity of
the assay used, 10–40% of infants with BA and 18–37% of
cholestatic infants without BA did exhibit positive IgM for
RV-A [21].
Jafri et al. [22] demonstrated that mouse cholangio-
cytes were susceptible to RV infection in vitro and that
inhibition of the mitogen-activated protein kinase (MAPK)
family signaling pathway reduced viral replication.Moreover,
mouse cholangiocytes respond to RV infection by expressing
chemokines in vitro, such asMCP-1, RANTES, KC, andMIP-
2, some of which have been implicated in the pathogenesis
of experimental BA [23]. More recently, the human cholan-
giocyte H69 cell line was also shown to be susceptible to RV
infection in a way that paralleled the murine model of BA
[24], providing a human in vitro model to further study the
pathogenic mechanisms involved in human BA.
Here we show that the human cholangiocyte H69 cell line
is susceptible to RV infection in vitro and that exposure of the
cells to RRV induces the secretion of IL-6 and IL-8, which
have been associated with BA in humans. Inhibition of the
MAPK family cell signaling pathway significantly reduced the
secretion of these cytokines. We confirm that RV infection
of human cholangiocytes can be a useful in vitro model for
investigating the viral hypothesis of acquired BA in humans.
Moreover, we provide clear evidence that human cholangio-
cytes in vitro can become immunoregulatory cells in response
to virus infection.
2. Materials and Methods
2.1. Cells and Virus. Rhesus kidney epithelial MA104 cells
(ATCC CRL-2378.1) were used to propagate RRV and were
grown in Medium 199 containing 5% (vol/vol) fetal bovine
serum (FBS), 1% penicillin/streptomycin, and 1% Fungizone
(Invitrogen, Carlsbad, CA). Human bile duct epithelial cells
(H69 cell line, a biliary epithelial cell line produced from nor-
mal human liver) were kindly provided by Drs. N. La Russo
andD. Jefferson andwere grown as previously described [25].
Prior to infection, RRV was activated by incubation in
Leibovitz medium (L-15, Invitrogen) containing 5 𝜇g/mL of
porcine trypsin (Sigma, St. Louis, MO) for 30 minutes (min)
at 37∘C [19]. Cell monolayers were infected at a multiplicity
of infection (MOI) of 1 to 5 plaque-forming units (PFUs)
per cell. Cells were incubated with viral inoculum for 60min
(MA104 cells) or 90min (H69 cells) at 37∘C. Viral inoculum
was replaced with FBS-free Eagle Minimal Essential Medium
(MEM) (Invitrogen) containing 0.05𝜇g of trypsin/mL. RRV
titers were determined by plaque assay on MA104 cells [26].
2.2. Indirect Immunofluorescence (IF) Assay. Cells were
seeded onto coverslips at a density of 5 × 104 cells/well in
6-well plates, infected with RRV or mock-infected, fixed
with 4% paraformaldehyde, and permeabilized with 0.5%
Triton-X100 in phosphate-buffered saline (PBS). The cells
were subsequently incubated with guinea pig anti-RV VP6
polyclonal antisera (1 : 2000 dilution) and, in some cases,
mouse anti-cytokeratins 7 and 19 monoclonal antibodies
(1 : 1000 dilution). The cells were then incubated with rabbit
anti-guinea pig Alexa Fluor 594 (1 : 1000; red signal) alone
or with rabbit anti-mouse Alexa Fluor 488 (1 : 1000; green
signal). Nuclei were stained with DAPI (4󸀠,6-diamidino-2-
phenylindole). Fluorescence was detected with an Olympus
BX460 fluorescence microscope (Olympus, Center Valley,
PA).
2.3. RNA Isolation and cDNA Synthesis. Total RNA was
isolated from 1 × 108 H69 cells using a NucleoSpin RNA L
kit (Clontech, Mountain View, CA) according to the protocol
of the manufacturer. Briefly, H69 cells were detached from
culture flasks by incubation with 0.05% trypsin-EDTA, pel-
leted by low-speed centrifugation, and resuspended in lysis
buffer. After homogenization, insoluble debris was removed
by centrifugation through filter L columns. After addition of
70% ethanol, RNAwas recovered from samples by binding to
RNA L columns.
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First-strand cDNA was synthesized from RNA using a
Superscript III Reverse Transcriptase kit (Invitrogen). Poly-
merase chain reaction (PCR) amplification was performed
using PlatinumTaqDNApolymerase (Invitrogen) in reaction
mixtures containing primers (Table 1) specific for human IL-
6, IL-8, MCP-1, TGF𝛽1, and GAPDH genes. After 2min of
an initial denaturation at 94∘C, cDNAs were amplified under
the following conditions: 30 seconds (sec) at 94∘C, 30 sec at
56∘C, and 1min at 72∘C for a total of 35 cycles (Programmable
Thermal Controller PTC-100, MJ Research Inc., Watertown,
MA). PCR products were resolved by electrophoresis on 1.5%
agarose gels and detected by staining with ethidium bromide
and exposing to ultraviolet light.
2.4. Quantitative Real Time PCR (qRT-PCR). qRT-PCR was
performed using JumpStart Taq Ready Mix (Sigma) and the
ABI 7900 HT Fast Real Time PCR system (Applied Biosys-
tem). qRT-PCR cycles included 2min of initial denaturation
at 94∘C, followed by 40 cycles of denaturation at 94∘C for
15 sec and annealing and extension at 60∘C for 1min. qRT-
PCR results were analyzed by the StratageneMx4000Quanti-
tative PCR system. Values were normalized to those obtained
for the housekeeping gene, GAPDH (glyceraldehyde-3-
phosphate dehydrogenase). For each specific gene, themRNA
relative expression in treated cells was reported as fold
difference from or percent (%) of untreated cells.
2.5. Human Cytokine-Expression Profile Analysis. Simulta-
neous detection of 23 human cytokines was performed in
culture supernatants from RRV- or mock-infected H69 cells,
using the human cytokine antibody array kit (C Series, AAH-
CYT-1 kit; Ray Biotech, Norcross, GA; the arraymap is shown
in Table 2).The antibody array membranes were blocked and
incubated with 1mL of undiluted culture supernatant for 2 h.
After washing, a cocktail of biotin-conjugated anti-cytokine
antibodies was added for 2 h, followed by 1 h incubation
with horseradish peroxidase-labeled streptavidin. After final
washes, chemiluminescence images were captured and digi-
tized using a laser-based scanner with charge coupled device
camera system (Fujifilm LAS-3000, R&D Systems Inc., Min-
neapolis, MN). Expression levels of cytokines were measured
using Fujifilm Multi Gauge software (R&D Systems).
2.6. Analysis of IL-6 and IL-8 Levels by Enzyme-Linked
Immunosorbent Assay (ELISA). IL-6, IL-8, and IL-10 levels in
the media of mock- or RRV-infected H69 cells at 24 and 48 h
p.i. were quantified with Pierce human IL-6, IL-8, or IL-10
colorimetric ELISA kits (Thermo Fisher Scientific, Rockford,
IL). The detection range is between 10 and 1000 pg/mL.
Samples above the maximum were diluted 1 : 2 in the reagent
diluent provided with the kit and retested.
2.7. Mitogen-Activated Protein Kinase (MAPK) Pathway Inhi-
bition. To study the effect of inhibition of MAPK pathways
on RRV-induced IL-6 and IL-8 secretion, H69 cells were
treated with the following MAPK inhibitors: an ERK1/2
inhibitor (U0126, Cell Signaling Technology, Inc., Danvers,
MA), a p-38 inhibitor (SB203580, Invitrogen), and a JNK
inhibitor (SP600125, EMD Biosciences, La Jolla, CA). All
three inhibitors were prepared by dissolving in dimethyl sul-
foxide (DMSO) at a concentration of 10mManddiluted 1000-
fold with culture medium. The final concentration of DMSO
was 0.1% in all experiments. Cell monolayers were initially
incubated for 2 h in L-15 medium containing 10𝜇M of an
inhibitor. Afterwards, the media were removed and the cells
were washed with L-15 medium.The cells were then infected
with RRV (MOI = 5) or mock-infected for 90min. The cells
were washed 3 times with PBS, and postinfection medium
with or without inhibitors (10𝜇M) was placed on the cells.
Levels of IL-6 and IL-8 in cell culture media recovered from
mock- or RRV-infected H69 cells at 24 and 48 h p.i. were
quantified using Pierce ELISA kits.
2.8. Statistics. Experiments were performed in duplicate
(immunofluorescence and human cytokine antibody array)
and triplicate (ELISA, qRT-PCR, and MAPK inhibition) and
were repeated 2 or more times (mock and RRV infection
of H69 cells). One-tailed Student’s 𝑡-test was performed to
compare the means of two populations. In the bar graphs,
data represent the mean ± standard deviation (SD) of mul-
tiple repeats. 𝜒2 test was performed to compare the values of
two populations. A 𝑝 value of less than 0.05 was considered
significant. The ∗𝑝 < 0.01 was used to indicate statistical
significance of differences between samples.
3. Results
3.1. Human Biliary Epithelial Cells Are Susceptible to Infection
by RRV. Infection of MA104 cells at an MOI of 1 with RRV
resulted in extensive cytopathic effects (CPE) and the loss of
the cell monolayer by 15 h p.i. In contrast, no cytolysis was
obvious in RRV-infected H69 cells at 24 h p.i. at an MOI
of either 1 or 5. Moreover, trypan-blue exclusion analysis
showed no difference in the viability of mock- and RRV-
infected cells at either 24 or 48 h p.i. However, IF assays with
RV VP6 antibody revealed the presence of viroplasms in the
cytoplasm of infected but not mock-infected H69 cells (Fig-
ures 1(a) and 1(b)). Specifically, ∼25% of RRV-infected H69
cells infected at an MOI of 5 contained viroplasms. IF assays
also showed that the infectedH69 cells expressed cytokeratins
7 (Figures 1(c)–1(e)) and 19 (data not shown), confirming
their bile duct epithelial histotype (Figures 1(c)–1(e)).
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Table 2: Array map.
A B C D E F G H
1 POS POS NEG NEG G-CFS GM-CFS GRO GRO-𝛼
2 POS POS NEG NEG G-CFS GM-CFS GRO GRO-𝛼
3 IL-1 𝛼 IL-2 IL-3 lL-5 IL-6 IL-7 IL-8 IL-10
4 IL-1 𝛼 IL-2 IL-3 lL-5 IL-6 IL-7 IL-8 IL-10
5 IL-13 IL-15 IFN 𝛾 MCP-1 MCP-2 MCP-3 MIG RANTES
6 IL-13 IL-15 IFN 𝛾 MCP-1 MCP-2 MCP-3 MIG RANTES
7 TGF𝛽1 TNF 𝛼 TNF 𝛽 BLANK BLANK BLANK BLANK POS
8 TGF𝛽1 TNF 𝛼 TNF 𝛽 BLANK BLANK BLANK BLANK POS
(a) (b)
(c) (d) (e)
Figure 1: Top panels: immunofluorescence staining of mock- (a) and RRV- (b) infected H69 cells (MOI of 5, 24 h p.i.) using anti-RV VP6
antibody; red cytoplasm fluorescence indicates RRV-infected cells (magnification 40x). Bottom panels: double immunofluorescence staining
with anti-RVVP6 (red, c) and CK-7 (green, d) antibodies of RRV-infectedH69 cells; (e) is amerged image of (c) and (d). Blue counterstaining
of nuclei by DAPI.
To test whether H69 cells supported productive replica-
tion of RRV, supernatants recovered at 2, 24, and 48 hp.i. from
RRV-infected and mock-infected H69 cells were analyzed by
plaque assay onMA104 cells.The results showed a progressive
increase in RRV titers, beginning with 102 PFU/mL at 2 h
p.i., reaching 106 PFU/mL at 24 h p.i. and 108 PFU/mL at
48 h p.i., Thus, the H69 cells represent a permissive cell line
for RRV growth. This conclusion was further supported by
transfer of “postinfection” medium from RRV-infected H69
cells onto MA104 cell monolayers, which resulted in the
complete cytolysis of the monolayers upon overnight incuba-
tion. As expected, transfer of “postinfection” medium from
mock-infected H69 cells to MA104 cells did not result in
cytolysis.
3.2. RRV-Infected Human Biliary Epithelial Cells and IL-6 and
IL-8 Cytokines. The presence of cytokines in the media of
mock-infected and RRV-infected H69 cells at 24 and 48 h
p.i. (MOI = 1) was screened using a cytokine antibody array
assay (Figure 2).The analysis showed that detectable levels of
GRO, GRO-𝛼, RANTES, and IL-8 were present in the media
of mock-infected H69 cells at 24 h p.i. RRV infection resulted
in higher levels of IL-6 and IL-8 accumulation in the media
and slightly higher levels of IL-7, IL-10, GRO, and GRO-𝛼 at
24 h p.i. as compared to mock infection (Figure 2). Likewise,
the levels of these cytokines, as well as RANTES, were higher
at 48 h p.i. than at 24 h p.i. in RRV-infected-cell media. These
results indicate that RRV infection stimulates the expression
of some cytokines by H69 cells, notably IL-6, IL-8, and IL-10,
which appears to increase overtime.
To validate and quantify the results obtained with the
cytokine antibody array assay, the concentrations of IL-6, IL-
8, and IL-10 in the media of mock-infected and RRV-infected
H69 cells (MOI = 1) were determined by ELISA. As above, the
results showed that little or no IL-6was present in uninfected-
cell media at 24 h p.i., with only low levels detectable in
















Figure 2: Results of the cytokine array antibody membrane assay: cytokines present in media of mock- and RRV-infected H69 cells at 24 (a)
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Figure 3: IL-6 (a) and IL-8 (b) detection by ELISA in media of mock- and RRV-infected cells at 24 and 48 h p.i. Bar graphs indicate the mean
± standard deviation (SD) of multiple repeats. Asterisks indicate significant difference between mock and RRV at each time point. ∗𝑝 value
<0.01 from mock-infected cells.
the media of such cells at 48 h p.i. (67.4 ± 13.9 pg/mL)
(Figure 3(a)). In contrast, infected-cellmedia contained read-
ily measurable IL-6 levels at 24 h p.i. (61.2 ± 1.9 pg/mL)
(𝑝 < 0.0001 for infected versus mock-infected) and even
greater levels at 48 h p.i. (458.8 ± 63.5 pg/mL) (𝑝 < 0.00020
for infected versus mock-infected). Not unexpectedly, IL-6
levels in the media were dependent on infection conditions,
with IL-6 concentrations 3.6-fold higher at an MOI of 5 than
at an MOI of 1 in RRV-infected cells at 24 h p.i. (𝑝 < 0.001;
Figure 4(a)) but not in mock-infected cells (Figure 4(a)). At
24 h p.i., IL-6 level was 76 ± 3.1 pg/mL at MOI = 1 versus
273± 22.8 pg/mL atMOI = 5 in RRV-infected cells, while IL-6
was undetectable in mock-infected cells at both MOI = 1 and
MOI = 5 (Figure 4(a)).
ELISA analysis revealed that, at 24 h p.i., IL-8 levels in
the media of RRV-infected H69 cells (556.5 ± 111 pg/mL)
were ∼7-fold higher than in the media of mock-infected cells
(77.0±68 pg/mL) (𝑝 < 0.0042 for RRV-infected versusmock-
infected) (Figure 3(b)). At 48 h p.i., levels of IL-8 in infected-
cell media (1558.6 ± 246 pg/mL) were approximately twice as












































Figure 4: IL-6 (a) and IL-8 (b) detection (pg/mL) by ELISA in media of mock- and RRV-infected H69 cells at 24 h p.i. (MOI = 1 and MOI =
5). Bar graphs indicate the mean ± standard deviation (SD) of multiple repeats. Asterisks indicate significant difference between mock and
RRV at each MOI. ∗𝑝 value <0.01 from mock-infected cells.
high as that of uninfected-cell media (760.0 ± 49.9 pg/mL)
(𝑝 = 0.011 for RRV-infected versus mock-infected). IL-8
media levels were also influenced byMOI, with levels 1.6-fold
higher in themedia of H69 cells infected with RRV at anMOI
of 5 than 1 (𝑝 < 0.001; Figure 4(b)). At 24 h p.i., IL-8 level was
870± 19.3 pg/mL atMOI = 1 versus 1442± 36 pg/mL atMOI =
5 in RRV-infected cells, while IL-8 was 220 ± 7.3 pg/mL at
MOI = 1 versus 153 ± 4.6 pg/mL at MOI = 5 in mock-infected
cells (Figure 4(b)). IL-10 was not detectable by ELISA in the
media of mock- or RRV-infected cells at either 24 or 48 h p.i.
(data not shown).
To further evaluate the effect of RRV infection on the
expression of cytokines in H69 cells, levels of IL-6 and IL-
8 mRNAs in mock and infected cells recovered at 24 h p.i.
were determined by qRT-PCR. As shown in Figure 5, IL-6
and IL-8mRNA levels were approximately 6-fold and 1.5-fold
higher, respectively, in infected H69 cells than in uninfected
cells. These results are consistent with those presented above
(Figures 2–4) which indicates that RRV infection stimulates
the expression of IL-6 and IL-8 cytokines by H69 cells. In
contrast, qRT-PCR analysis revealed that RRV infection had
no impact on the mRNA levels of two other cytokines, MCP-
1 and TGF𝛽1, used as negative controls in these experiments
(data not shown).
3.3. Effect of MAPK Inhibitors on IL-6 and IL-8 in RRV-
Infected H69 Cells. The importance of MAPK activation in
the release of IL-6 and IL-8 from RRV-infected H69 cells
was examined using the MAPK inhibitors to ERK 2/1, p-38,
and JNK. No difference in the viability of mock- and RRV-
infected cells treated with the MAPK inhibitors (which were
dissolved in 0.1%DMSO)was found by trypan-blue exclusion
at either 24 or 48 h p.i. Treatment of RRV-infected H69 cells
with SB203580 (p-38 inhibitor) had the greatest effect on IL-
6 and IL-8 accumulation in media, as assessed by ELISA,
reducing their levels by ∼90% (Figure 6(a)). In contrast,
U0126 and SP600125 (ERK 1/2 and JNK inhibitors, resp.)














































Figure 5: qRT-PCR results: relative expression of IL-6 and IL-8
mRNAs at 24 h p.i. in RRV-infected H69 cells expressed as fold
difference from mock. ∗𝑝 value <0.01.
The effect of the MAPK inhibitors on IL-6 and IL-8
mRNA expression was analyzed by qRT-PCR. As shown in
Figure 6(b), treatment of RRV-infected cells with SB203580
decreased mRNA expression of both IL-8 (11% of values
observed in RRV-infected cells not treated with inhibitor)
and IL-6 (28%). When RRV-infected cells were treated
with U0126, mRNA expression of IL-8 was 34% of values
observed in RRV-infected cells not treated with inhibitor.
RNA expression of IL-8 mRNA was not affected when RRV-
infected cells were treated with SP600125; mRNA expression
of IL-6 was 70% of values observed in RRV-infected cells not
treated with SP600125.
Results of the plaque assay experiments showed that the
treatment with any of the three MAPK inhibitors did not
affect the replication of RRV, as this treatment did not affect
the titer of RRV in infected H69 cells.
































































































Figure 6: (a) IL-6 and IL-8 levels, measured by ELISA, in the media of RRV-infected H69 cells treated withMAPK inhibitors (p-38, ERK 1/2,
and JNK inhibitors), expressed as % of untreated RRV-infected cells. (b) IL-6 and IL-8 mRNA levels, measured by qRT-PCR, in RRV-infected
H69 cells treated with MAPK inhibitors (p-38, ERK 1/2, and JNK inhibitors), expressed as fold difference from untreated RRV-infected H69
cells. Bar graphs indicate the mean ± standard deviation (SD) of multiple repeats.
4. Discussion
This study confirms that human biliary epithelial cells are
susceptible to productive infection with RRV. RRV infection
of human biliary epithelial cells in vitro was associated with
the increased release of proinflammatory and profibrotic
cytokines, such as IL-6 and IL-8, into the media of infected
cells. Inhibition of MAPK cell signaling pathway resulted in
decreased amounts of both cytokines in the media.
Unlike infection of MA104 cells with RRV, RRV infec-
tion of human biliary epithelial cells was not cytolytic but
resulted in the release of infectious virions into the cell
culture medium, from which infection could be transmitted
to MA104 cells with resultant cytolysis. Furthermore, RRV
infection of human biliary epithelial cells resulted in a time-
dependent increase in the supernatant levels of two proin-
flammatory and profibrotic cytokines, IL-8 and IL-6. Treat-
ment of the infected cells with a MAPK p-38 inhibitor was
associatedwith amarked reduction in the amount of IL-6 and
IL-8 detectable in the supernatant.
Themitogen-activated protein kinase (MAPK) pathway is
one of the intracellular signaling pathways that are activated
in response to RV infection in different epithelial cell lines,
including mouse cholangiocytes [22]. Following RV infec-
tion, activation of the MAPK cascade leads to the upregu-
lation of cellular genes. In a human intestinal epithelial cell
line (Caco2), RV infection has been reported to be associated
with a significant increase in the expression of IL-8 through
MAPK p-38 [27]. The promoter of the IL-8 gene has been
found to have a binding site for AP-1, which is the last protein
to be activated in the MAPK p-38 intracellular cascade [27].
Human cholangiocytes are known to release both IL-6
and IL-8 in response to a variety of injuries in vivo [28, 29].
Release of IL-6 occurs when human cholangiocytes are
exposed to bacterial lipopolysaccharide [30]. MAPK activity
increases in a time- and dose-dependent way in RV-infected
mouse cholangiocytes both in vitro and in vivo, where it is
associated with increased production of inflammatory
chemokines [22, 23].
Interestingly, as noted above, these two proinflammatory
and profibrotic cytokines are thought to be major mediators
of tissue damage in acquired BA. Moreover, analysis of BA
livers by microarray and qRT-PCR demonstrated promi-
nent expression of proinflammatory genes at early stages of
acquired BA, where IL-8 was by far the most upregulated
gene (a 17-fold increased expression compared to livers of
infants with other cholestatic disorders) [31]. Elevated serum
IL-8 has been detected in BA infants with jaundice and/or
portal hypertension [32, 33], and the serum concentration
of IL-6 has been found to correlate with the severity of BA
[34]. IL-6 is released from biliary epithelial cells during liver
injury where it directly promotes cell proliferation allowing
cell survival and regeneration [35].Thus IL-6 secretionmight
represent ameans of defense for human biliary epithelial cells
to control and to survive the viral infection, explaining why
RRV infection did not result in H69 cell lysis in vitro [35].
It is interesting to note that the RRV-infected media which
resulted in cytolysis in MA104 cells contained both RRV and
cytokines. Either IL-6 or possibly other cytokines might have
differential effects on cell survival in MA104 and H69 cells
or the differential survival of the two cell types in response
to RRV infection may be explained by factors other than
cytokines.
We should note that our results do not imply a causal role
for RV alone in BA especially given our recent observation
that the prevalence of RV infection in BA versus other
cholestasis disorders (10–40% in BA versus 18–37% in other
cholestatic infants) was almost identical [21]. If RV (or any
other virus) plays any role in BA, genetically determined
differences in immune response to viral infections are likely
involved, including differential cytokine responses. As we
noted [21] there is substantial precedent for differential host
immune responses to infections with other viruses such as
hepatitis C virus and HIV.
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Our observations that RRV infection of human cholan-
giocytes involves MAP kinase activation suggests another
intriguing avenue by which viral infection might be impli-
cated in the pathogenesis of BA, as prolonged activation of
this kinase induced by a viral infection early in life might lead
to unbalanced expression of cytokines such as IL-6 and IL-8,
which have been associated with progression toward a severe
BA phenotype.
In the well-known experimental murine model of RRV-
induced BA-like disease, where the hepatobiliary disease
progresses in the absence of detectable virus, the potential
therapeutic use of MAPK blockers could be explored.
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